OneMedForum New York 2010 - Company Presentation. Access Pharmaceuticals, Inc., a emerging biopharmaceutical company that focuses on adding value to exciting product concepts in research by advancing those products through clinical development.

1. OneMedForum New York – Emerging Company Conference The Roosevelt Hotel – June 30, 2010 Investor Presentation June 2010 www.accesspharma.com

2. This presentation contains certain statements that may be forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, including statements relating to the product portfolio and pipeline and clinical programs of the combined company, the market opportunities for MuGard™, the sales of, market opportunities for and planned studies of ProLindac™, the market opportunities for Thiarabine and the Cobalamin programs, and the combined company’s goals and objectives. These statements are subject to numerous risks and uncertainties, including but not limited to the risks detailed in Access's Annual Report on Form 10-KSB for the year ended December 31, 2009, and other reports filed by the companies with the Securities and Exchange Commission. These materials are not an offer to sell securities and are not soliciting an offer to buy securities. For Additional Access Pharmaceuticals Information, Go to the Following Publicly Available Resources: www.AccessPharma.com at AccessPharma at Access Pharmaceuticals 2 Safe Harbor Statement

4. Deep Late Stage Products – Access has late-stage products, including FDA-approved MuGard, and ProLindac and Thiarabine (through multiple Phase II trials).

5. Partnering Strategy – Access has completed eight partnerships or collaborations in the past 24 months: upfront payments, royalties, research costs, clinical costs.

6. Experienced Team –Experienced chemists, pre-clinical and manufacturing experts, clinical development personnel, and business development and finance personnel.

7. Focus on Shareholder Value – Management and board members are significant shareholders, focused on increasing shareholder value.3 Corporate Overview & Highlights Access Pharmaceuticals, Inc.(ACCP.OB) – a drug delivery company with late-stage products for cancer, diabetes and hormone replacement. Several products are based on Access’ proprietary drug delivery platform technologies.

8. 4 Multiple Platforms Drives Opportunity Two proprietary, drug-delivery platform technologies enable product development across multiple biotechnology sub-sectors: Cancer, Diabetes, Hormone, Fertility, etc..

9. 5 MuGard –FDA-approved cancer supportive care product

10. MuGard™ - Treating A Significant Health Issue Oral Mucositis:Significant Medical Issue – Often Unrecognized, Undiagnosed and Undertreated 6

12. MuGard Stands Alone:Only FDA-approved product that instructs pre-treatment; Safe to swallow

13. Multiple Marketing Partners: Partners signed for EU, Switzerland, Norway, Iceland, China, Korea; US manufacturing completed – launch activities commencing

14. Royalties: 20%, scaling to 25%7 MuGard™ - Oral Mucositis (OM) European Launch Underway; North American / Far East Launch Soon Royalties Start This Year

15. MuGard’s Industry Leading Label Indications: indicated for the management of pain and relief of pain… Directions for use: Gargle and spit out. Indications: dryness or dry mouth associated with various conditions Directions for use: Swish and spit out. Indications: “Magic Mouthwash" prepared by pharmacists and used to treat mouth sores (oral mucositis) Directions for use: Gargle and spit out Indications: MuGard is indicated for the management of oral mucositis/ stomatitis Directions for use: … rinse may be expelled or swallowed … safe to swallow … …recommended that patients purchase MuGard™prior to the commencement of cancer therapy .. MuGard is recommended for preventative use MuGard can be swallowed to coat lesions in throat 8

17. Key opinion leader collaboration (Dr. Stephen Sonis) – Oral Mucositis expert

18. MuGard Centers-of-Excellence Program – targeting large oncology networks to build awareness and clinical experience with MuGard

19. Work with reimbursement consultants – filed reimbursement coding application and discussions are ongoing with major third-party payers

20. Key Clinical Data – presented last week at MASCC and ongoing throughout the year; supports prevention, treatment, pain relieve, ease-of-use

21. Secure additional distribution channels

22. Long-term stability for full commercial availability – on schedule for late July

23. Additional MuGard partnerships9 ACCP Remains On-track for Full-Scale North American MuGard Launch

24. 10 Cobalamin– oral drug delivery platform to enhance absorption of large molecules

25. 11 1 2 3 4 Cobalamin Oral Drug Delivery Platform Using The Body’s Own Vitamin B-12 Absorption System To Enable and Enhance Delivery of Drugs Through Gut Wall The “Trojan Horse” Delivery Vehicle The nanoparticle coated with Cobalamin (red) binds to intrinsic factor (1), which in turn binds to its cell surface receptor (2). The nanoparticle is transported across the cell (3), crosses the gut wall and enters the bloodstream (4). Nanopolymer “payload” can be Insulin, growth hormone, EPO, etc.

27. Two Ongoing Collaborations– Oral insulin provided to two collaborators that have confirmed high levels of oral bioavailability with Cobalamin oral insulin

28. Cobalamin Human Growth Hormone– Demonstrated high oral bioavailability and a 25% improvement in weight gain in standard animal model

29. Multiple Applications– Ongoing discussions with multiple potential partners looking at exploiting Cobalamin oral drug delivery for insulin, HGH, fertility drugs, proteins, etc.

30. Patent Life-cycle Management Tool –protect patent (IP) position through cobalamin formulation of existing drugs, resulting in new IP

31. Phase I Human Trial– Moving Cobalamin oral insulin into a proof-of-concept Phase 1 study in man

34. Eloxatin®

35. FDA approved (2001) for front-line metastatic colorectal cancer

36. 2008 $2.5+ billion projected sales globally

37. Significant neurotoxicity

38. Partnering On-going– Partnered with Aosaikang Med Group (ASK) in China and JCOM in Korea. Partners paid upfront, committed to run 3 clinical trials that ACCP controls, and royalties.DACH Platinum (same active in Eloxatin) is inactive while attached to polymer background Chelator releases platinum compound in low pH environment; e.g. tumor

40. 36 patients enrolled in six centers in France; final follow-up ongoing

41. Heavily treated patients (at least 3, up to 7, previous regimens)

42. Exploring two dosing schedules (once/two weeks and once/three weeks)

43. Safety – ProLindac Exhibited Very Benign Safety Profile

44. Patients tolerating drug well through multiple cycles (up to 10 or more)

45. No Eloxatin-like neurotox; no nephrotox; no hematotoxicity; no worse emesis

46. Efficacy and Activity – ProLindac “Outperforms” Current Best Care

47. At highest doses, 66.7% ProLindac patients responded; Activity levels superior to oxali or carbo in monotherapy in similar but healthier patient populations (approx 20%)

48. Next Steps

49. Combination trials: Partners ASK and JCOM paying for three Access-designed and managed Phase 2/3 trials: ProLindac plus taxol in recurrent ovarian and ProLindac plus Lilly’s Gemzar in liver and pancreatic cancer; additional combination studies possible in other tumor types

50. Partnering discussions ongoing15 ProLindac™ Phase II Trial – Relapsed Ovarian Final Study Results – Safe and Active DACH Platinum Drug

51. 16 Thiarabine– Phase II cancer drug for Leukemias and Lymphomas

53. Significant Data/Information Known – Drug was well tolerated and active in two Phase 2 clinical trials in advanced solid tumors. Significant clinical pharmacology and dose scheduling information known.

54. MD Anderson Cancer Center – Principal investigator is Hagop Kantarjian, M.D., Head of Leukemia Dept. at MD Anderson(same team of experts that have successfully led to approved nucleoside analogues in leukemias and lymphomas).

56. Aosaikang Medicinal Group (ASK)–Rights to ProLindac in greater China; provides second source manufacturing; obligated to pay for two controlled combination studies

57. JCOM Ltd – Rights to ProLindac in Korea; obligated to pay for one pivotal controlled combination study.

58. JCOM Ltd–Rights to MuGard in Korea; securing regulatory approval and preparing commercial launch in 2010

59. RHEI Pharma: – Rights to MuGard in greater China; securing regulatory approval, and seeking source of supply; preparing for commercial launch

60. US Large Pharma – Sponsored research agreement evaluating cobalamin oral drug delivery platform (insulin and human growth hormone)

61. US and European Biotechnology Company –Material transfer agreement and collaboration agreement; evaluating cobalamin oral insulin in animal models 18 Active Partnering Strategy For Drug Programs Active Business Development Effort; Securing Partnerships and Collaborations to Enhance Value and Share Costs

62. Jeffrey B. Davis, Chief Executive Officer:President, SCO Financial Group LLC; Sr. VP and CFO of a healthcare technology company; VP, Corporate Finance, at Deutsche Morgan Grenfell; Senior marketing and product management positions at AT&T Bell Laboratories; Marketing and Product Manager at Philips Medical Systems North America. MBA, The Wharton School, University of Pennsylvania; BS Biomedical Engineering, Boston University. Esteban Cvitkovic, M.D., Vice Chairman, Senior Director, Clinical Oncology R&D: Board-certified oncologist with over 30 years experience in oncology therapeutics, including clinical research, clinical pharmacology, design of single-agent and combination regimens, and optimization of clinical efficacy; played a fundamental role in the registration strategy and post-registration development of cisplatin and oxaliplatin; held staff and academic appointments at Memorial Sloan Kettering Cancer Center (NY), Columbia Presbyterian (NY), Hospital St. Louis (Paris), Instituto Mario Negri (Milan) and InstitutGustaveRoussy (Villejuif). Frank Jacobucci, Vice President Sales & Marketing: Over 20 years experience in sales management, including senior sales executive positions at oncology focused companies including MGI Pharma, Genetics Institute, Wyeth Oncology, Aventis, Precision Therapeutics and CRC Oncology Services. David P. Nowotnik, Ph.D., Senior Vice President Research and Development:Senior Director, Product Development, Guilford Pharmaceuticals, Inc.; Group Leader, Bristol-Myers Squibb. Section Leader, Amersham International. Research Chemist, Tate and Lyle and Aspro-Nicholas. PhD, Organic Chemistry, University of London. Stephen B. Thompson, Vice President and CFO: Controller and Administration Manager, API; Controller, Robert E. Woolley, Inc., a hotel real estate company; Controller, OKC Limited Partnership, an oil and gas company. Accounting and finance, Santa Fe International Corporation. Phillip Wise, Vice President Business Development and Strategy: VP, Commercial and Business Development and CFO, Enhance Pharmaceuticals; VP, Commercial and Business Development, Ardent Pharmaceuticals; Director of Managed Care Marketing & Director of New Product Planning, GlaxoWellcome; MBA, University of Virginia; BS, Industrial and Systems Engineering, Georgia Institute of Technology. 19 Experienced Management Team

64. Esteban Cvitkovic, M.D., Vice Chairman – see Management

65. Mark Ahn, Ph.D.Dr. Ahn is currently Professor and Chair of the Science & Technology Entrepreneurship Faculties of Commerce & Administration and Science at the Victoria University of Wellington, in Wellington, New Zealand. Previously, Dr. Ahn was President and CEO of Hana Biosciences, Inc., and earlier, Vice President Hematology at Genentech, Inc. where he was responsible for Rituxan. Prior to that, Dr. Ahn held senior positions at Bristol-Myers Squibb, Amgen and FMC Corporation.

66. Mark AlvinoMark Alvino is a Managing Director at Griffin Securities, a leading provider of corporate finance advisory and brokerage services to the life sciences industry. Prior to that, Mark was a Managing Director for SCO Securities, and additionally held several senior management positions within the investment banking and investor relations industries

67. Stephen B. Howell, M.D.Dr. Howell is Professor of Medicine, University of California at San Diego, and has extensive experience in platinum therapeutics. Dr. Howell is also a Director of Clinical Investigation and Development Therapeutics Program, UCSD Cancer Center, and has previously received the Milken Foundation prize for contributions to cancer chemotherapy.

68. Jeffrey B. Davis, Chief Executive Officer – see Management20

70. Applying to Nasdaq and NYSE-AMEX exchanges

72. Cash Burn: Roughly $4 million annually. With current cash on balance sheet and expected upfront and milestone payments, Access has sufficient cash into 2011.

73. High Quality Institutional Investors: Includes SCO Capital Partners, Oracle Partners, Ramius, CSFB, Schroeder’s Bank21 Financial Overview

75. MuGard approval in Korea

76. bioRASI collaboration (Cobalamin first-in-man trial)

77. Key opinion leader collaboration (Dr. Stephen Sonis)

78. North American / Far East launches of MuGard

79. Additional MuGard clinical data, ongoing and at MASCC

80. Additional MuGard partnerships

81. Cobalamin preclinical data; additional partnerships and collaborations

82. Launch Phase 1 Cobalamin oral insulin trial

83. Initiate ProLindac combination Phase 2 trial; data available

84. Seek global or regional partnerships for ProLindac (discussions ongoing)

85. Secure additional investment banking research analyst coverage22

87. Late Stage Oncology Pipeline: Proprietary technology has created portfolio of new products for large markets

88. One FDA-Approved product, MuGard – North American launch; intro in Europe underway; Asia next; >$1 billion opportunity

89. One Phase 2/3-ready cancer drug, ProLindac – New form of proven drug, takes direct aim at Sanofi’s $2.5 billion Eloxatin franchise

90. One Phase 2-ready cancer drug, Thiarabine – superior version of clinically and commercially successful nucleoside analogue

91. Commercial Strategy: Multi-local development and marketing partners to shift risk and share costs, while retaining very attractive revenue/royalty rights.

92. Value Visibility: Seek “re-listing” on national exchange; actively present company to the investment community.23 Conclusions – Investment Highlights ACCP – An Undervalued Investment Opportunity